1266 related articles for article (PubMed ID: 31511088)
1. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
2. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
[TBL] [Abstract][Full Text] [Related]
4. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
[TBL] [Abstract][Full Text] [Related]
6. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
9. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
[TBL] [Abstract][Full Text] [Related]
10. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
11. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
[TBL] [Abstract][Full Text] [Related]
12. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
14. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
[TBL] [Abstract][Full Text] [Related]
18. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
